Oculis (NASDAQ:OCS) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Oculis (NASDAQ:OCS) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $36.00 price objective on the stock.

Other equities research analysts have also issued research reports about the company. Wall Street Zen lowered Oculis from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. Chardan Capital restated a “buy” rating and issued a $51.00 price target on shares of Oculis in a research note on Tuesday. Finally, HC Wainwright upped their price target on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.50.

Oculis Stock Performance

Oculis stock opened at $19.40 on Tuesday. Oculis has a 12-month low of $14.00 and a 12-month high of $23.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.55 and a quick ratio of 4.55. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -7.70 and a beta of 0.30. The firm’s fifty day moving average price is $19.05 and its 200 day moving average price is $18.62.

Oculis (NASDAQ:OCS) last announced its earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.10. Oculis had a negative return on equity of 83.21% and a negative net margin of 12,915.42%.The company had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.23 million. On average, research analysts forecast that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently modified their holdings of OCS. Kestra Private Wealth Services LLC acquired a new stake in Oculis during the first quarter worth about $234,000. Bosun Asset Management LLC bought a new position in shares of Oculis during the second quarter valued at approximately $378,000. Marshall Wace LLP acquired a new stake in shares of Oculis during the 2nd quarter worth approximately $393,000. Geode Capital Management LLC lifted its holdings in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.